Tianeptine Affects the Improvement of Behavioral Defects, Such As Schizophrenia, Caused by Maternal Immune Activation in the Mice Offspring

Overview

Journal Cent Nerv Syst Agents Med Chem

Publisher Bentham Science Publishers

Specialties Chemistry
Neurology
Pharmacology

Date 2023 Sep 6

PMID 37670703

Authors

Jun-Tack Kwon

Kooseung Jung

Affiliations

Soon will be listed here.

Abstract

Background: Simultaneously with studies on animal models of fetal-induced maternal immune activation, related studies documented behavior, neurophysiological, and/or neurochemical disorders observed in some neuropsychiatric disorders, including autism and schizophrenia.

Objective: To investigate whether treatment tianeptine might ameliorate maternal immune activation (MIA)-induced behavioral deficits in the offspring.

Materials And Methods: The pregnant mice were injected through tail vein injection at a concentration of 5 mg/kg of polyriboinosinic-polyribocytidilic acid (polyI:C) and/or used saline as a vehicle. The injection was performed on the 9th day of pregnancy. Each group of MIA offspring was subjected to vehicle, clozapine, or tianeptine treatment.

Results: In prepulse inhibition (PPI) test, oral treatment with tianeptine ameliorated MIA-induced sensorimotor gating deficit. Most behavioral parameters of social interaction test (SIT), forced swimming test (FST), and open field test (OFT) were significantly changed in the MIA offspring. Tianeptine treatment significantly recovered behavioral changes observed in the SIT, OFT, and FST. In order to confirm expression level of neurodevelopmental proteins, immunohistochemical image analysis and Western blot were performed, and the medial prefrontal cortex (mPFC) was targeted. As a result, it was confirmed that the neurodevelopmental proteins were decreased, which was recovered after administration of tianeptine to MIA offspring.

Conclusion: Tianeptine might be useful for treating psychiatric disorders with neurodevelopmental issues.

References

Braff D, Geyer M, Swerdlow N . Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001; 156(2-3):234-58. DOI: 10.1007/s002130100810. View

Meyer U, Feldon J, Fatemi S . In-vivo rodent models for the experimental investigation of prenatal immune activation effects in neurodevelopmental brain disorders. Neurosci Biobehav Rev. 2009; 33(7):1061-79. DOI: 10.1016/j.neubiorev.2009.05.001. View

McEwen B, Chattarji S, Diamond D, Jay T, Reagan L, Svenningsson P . The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry. 2009; 15(3):237-49. PMC: 2902200. DOI: 10.1038/mp.2009.80. View

Castanon N, Konsman J, Medina C, Chauvet N, Dantzer R . Chronic treatment with the antidepressant tianeptine attenuates lipopolysaccharide-induced Fos expression in the rat paraventricular nucleus and HPA axis activation. Psychoneuroendocrinology. 2002; 28(1):19-34. DOI: 10.1016/s0306-4530(02)00005-7. View

Law A, Harrison P . The distribution and morphology of prefrontal cortex pyramidal neurons identified using anti-neurofilament antibodies SMI32, N200 and FNP7. Normative data and a comparison in subjects with schizophrenia, bipolar disorder or major depression. J Psychiatr Res. 2003; 37(6):487-99. DOI: 10.1016/s0022-3956(03)00075-x. View

Lee H, Lee M, Kim H, Kim Y, Kwon J, Kim H . Influence of clozapine on neurodevelopmental protein expression and behavioral patterns in animal model of psychiatric disorder induced by low-level of lead. Korean J Physiol Pharmacol. 2019; 23(6):467-474. PMC: 6819901. DOI: 10.4196/kjpp.2019.23.6.467. View

Lewis D, Glantz L, Pierri J, Sweet R . Altered cortical glutamate neurotransmission in schizophrenia: evidence from morphological studies of pyramidal neurons. Ann N Y Acad Sci. 2003; 1003:102-12. DOI: 10.1196/annals.1300.007. View

Meyer U, Spoerri E, Yee B, Schwarz M, Feldon J . Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia. Schizophr Bull. 2008; 36(3):607-23. PMC: 2879685. DOI: 10.1093/schbul/sbn131. View

Meyer U, Feldon J . Neural basis of psychosis-related behaviour in the infection model of schizophrenia. Behav Brain Res. 2009; 204(2):322-34. DOI: 10.1016/j.bbr.2008.12.022. View

10.

Bitanihirwe B, Peleg-Raibstein D, Mouttet F, Feldon J, Meyer U . Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia. Neuropsychopharmacology. 2010; 35(12):2462-78. PMC: 3055332. DOI: 10.1038/npp.2010.129. View

11.

Barros C, Calabrese B, Chamero P, Roberts A, Korzus E, Lloyd K . Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system. Proc Natl Acad Sci U S A. 2009; 106(11):4507-12. PMC: 2657442. DOI: 10.1073/pnas.0900355106. View

12.

Plaisant F, Dommergues M, Spedding M, Cecchelli R, Brillault J, Kato G . Neuroprotective properties of tianeptine: interactions with cytokines. Neuropharmacology. 2003; 44(6):801-9. DOI: 10.1016/s0028-3908(03)00066-2. View

13.

Kuipers S, Trentani A, van der Zee E, den Boer J . Chronic stress-induced changes in the rat brain: role of sex differences and effects of long-term tianeptine treatment. Neuropharmacology. 2013; 75:426-36. DOI: 10.1016/j.neuropharm.2013.08.018. View

14.

Meyer U, Feldon J, Schedlowski M, Yee B . Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev. 2005; 29(6):913-47. DOI: 10.1016/j.neubiorev.2004.10.012. View

15.

Sanchez-Mateo C, Darias V, Albertos L, Exposito-Orta M . Psychopharmacological effects of tianeptine analogous hetero[2,1] benzothiazepine derivatives. Arzneimittelforschung. 2003; 53(1):12-20. DOI: 10.1055/s-0031-1297064. View

16.

Powchik P, Davidson M, Haroutunian V, Gabriel S, Purohit D, Perl D . Postmortem studies in schizophrenia. Schizophr Bull. 1998; 24(3):325-41. DOI: 10.1093/oxfordjournals.schbul.a033330. View

17.

Castanon N, Medina C, Mormede C, Dantzer R . Chronic administration of tianeptine balances lipopolysaccharide-induced expression of cytokines in the spleen and hypothalamus of rats. Psychoneuroendocrinology. 2004; 29(6):778-90. DOI: 10.1016/S0306-4530(03)00142-2. View

18.

Lucassen P, Fuchs E, Czeh B . Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal dentate gyrus and temporal cortex. Biol Psychiatry. 2004; 55(8):789-96. DOI: 10.1016/j.biopsych.2003.12.014. View

19.

Brown A, Sourander A, Hinkka-Yli-Salomaki S, McKeague I, Sundvall J, Surcel H . Elevated maternal C-reactive protein and autism in a national birth cohort. Mol Psychiatry. 2013; 19(2):259-64. PMC: 3633612. DOI: 10.1038/mp.2012.197. View

20.

Glantz L, Lewis D . Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry. 2000; 57(1):65-73. DOI: 10.1001/archpsyc.57.1.65. View